⌘K

Home/Filings/4/0000875320-24-000099

4//SEC Filing

Arbuckle Stuart A 4

Accession 0000875320-24-000099

CIK 0000875320other

View on SEC.gov Company Profile

Filed

Feb 26, 7:00 PM ET

Accepted

Feb 27, 4:37 PM ET

Size

6.8 KB

Accession

0000875320-24-000099

Insider Transaction Report

Form 4

Period: 2024-02-23

VERTEX PHARMACEUTICALS INC / MAVRTX

Arbuckle Stuart A

EVP\Chief Commercial Officer

Transactions

Tax Payment
Common Stock
2024-02-23$431.79/sh−4,714$2,035,458→ 54,725 total
Sale
Common Stock
2024-02-26$425.70/sh−5,034$2,142,974→ 49,691 total

Holdings

Common Stock
(indirect: By 401(k))
140

Footnotes (1)

[F1]Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1, which was entered into on 02/28/2023.

Documents

1 file

4
wk-form4_1709069823.xmlPrimary
FORM 4

Issuer

VERTEX PHARMACEUTICALS INC / MA

CIK 0000875320

Entity typeother

Related Parties

1

filerCIK 0001557290

Filing Metadata

Form type: 4
Filed: Feb 26, 7:00 PM ET
Accepted: Feb 27, 4:37 PM ET
Size: 6.8 KB

View on SEC.gov